𝔖 Bobbio Scriptorium
✦   LIBER   ✦

TREATMENT OF LUPUS NEPHRITIS WITH CYCLOPHOSPHAMIDE

✍ Scribed by STEWARTCAMERON, J

Book ID
122698626
Publisher
The Lancet
Year
1970
Tongue
English
Weight
537 KB
Volume
296
Category
Article
ISSN
0140-6736

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The economic impact of treatment of seve
The economic impact of treatment of severe lupus nephritis with prednisone and intravenous cyclophosphamide
✍ Pamela M. Mcinnes; James Schuttinga; William R. Sanslone; Susan P. Stark; John H πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 709 KB

Objective. It has been reported that outcomes are improved in patients with severe lupus nephritis treated with combined prednisone and intravenous cyclophosphamide, compared with those treated with prednisone alone. These findings motivated this analysis of the economic impact of the combined thera

Histopathologic and clinical outcome of
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
✍ Iva Gunnarsson; Birgitta Sundelin; Thorunn JΓ³nsdΓ³ttir; Stefan H. Jacobson; Elisa πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells. Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be of benefit in B cell–dependent diseases, including systemic lupus erythematosus (SLE). The purpose